Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol
- 30 November 2014
- journal article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 23 (6), 1741-1748
- https://doi.org/10.1007/s00520-014-2535-2
Abstract
In a longitudinal observation, extravasation of antitumoural compounds and the efficacy of its structured interdisciplinary management were assessed in a routine setting. One hundred sixty-nine patients with extravasation of cytotoxics were managed according to a prospective approach documenting the extravasated compound, localisation, duration until full symptom resolution and sequelae. Surgery was implemented in the case of failure of conservative measures. In 155 (91.7 %) out of 169 patients, conservative management was successful (surgical intervention, 14 patients). Extravasations of anthracyclines (N = 44), platinum compounds (N = 41), vinca alkaloids (N = 20) and taxanes (N = 19) were often associated with erythema, oedema and pain. The median period until full resolution of symptoms differed among the administered cytotoxics (anthracyclines, 55 days; taxanes and vinca alkaloids, 27 days; platinum compounds, 14 days) with statistical significance between the vesicants. Histologically, surgically resected specimens showed extensive necrotic areas with inflammatory infiltrates at the periphery of the removed lesions. In a routine setting, the standardised management of cytotoxic extravasations by an interdisciplinary task force resulted in a satisfactory outcome. When surgical intervention was indicated, complete remission of the lesions within a median of 14 days reduced the delay in the administration of further chemotherapy to a minimum. The proposed approach is therefore considered as suitable to manage extravasations in cancer chemotherapy in a large number of subjects and to ensure patient adherence to cytotoxic treatment.Keywords
This publication has 23 references indexed in Scilit:
- Recognition of a New Chemotherapeutic Vesicant: Trabectedin (Ecteinascidin-743) Extravasation With Skin and Soft Tissue DamageJournal of Clinical Oncology, 2009
- Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studiesAnnals of Oncology, 2006
- Effects of Heparin Fractions on the Prevention of Skin Necrosis Resulting From Adriamycin Extravasation: An Experimental StudyAnnals of Plastic Surgery, 2002
- Lack of Vesicant Injury Following Extravasation of Liposomal DoxorubicinJNCI Journal of the National Cancer Institute, 1995
- Hyaluronidase as an antidote to extravasation ofVinca alkaloids: Clinical resultsZeitschrift für Krebsforschung und Klinische Onkologie, 1994
- Local Soft Tissue Toxicity Following Cisplatin ExtravasationJNCI Journal of the National Cancer Institute, 1990
- Histologic changes induced in skin by extravasation of doxorubicin (adriamycin)Journal of Cutaneous Pathology, 1989
- Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugsCancer Treatment Reviews, 1980
- Major intravenous extravasation injuriesThe American Journal of Surgery, 1979
- Histopathogenesis of Skin and Subcutaneous Injury Induced by AdriamycinPlastic and Reconstructive Surgery, 1979